VERQUVO™ (vericiguat), a Bayer product, may not be the best choice for individuals with von Willebrand disease (vWF types 2 and 5), lupus, and antiphospholipid syndrome (APS) due to its effects on blood vessels and potential interactions with clotting disorders.